| Audience | Patients, clinicians, healthcare providers, researchers, and policy analysts. |
| Primary Topic | Clinical study review: Frequent Cannabis Use Linked With Higher Seizure B. |
| Source | Read the full source |
Frequent Cannabis Use Linked With Higher Seizure Burden in Drug-Resistant Epilepsy
A small EMU cohort found frequent cannabis users with drug-resistant epilepsy had more focal to bilateral tonic-clonic seizures and greater medication burden, but the study cannot prove cannabis caused worse epilepsy.
| Post Type | Physician-Guided Clinical Science Deep Dive |
| Primary Source | Epilepsia |
| Publication Date | 2026Sep28 |
| Evidence Level | Journal Article |
| Focus Area | Frequent Cannabis Use Linked With Higher Seizure Burden in D |
| Lead Authors | Santiago Philibert-Rosas, Kaitlin A Guston, Mariel Kalkach-Aparicio, Abigail Keller et al. |
| DOI | 10.1002/epi.70456 |
| PMID | PMID: 42803888 |
Mainstream Media Claim: Frequent cannabis use makes drug-resistant epilepsy worse and increases dangerous seizures.
Primary Journal Data: In 64 adults admitted to a tertiary EMU, 22 frequent cannabis users had higher FBTCS prevalence than 42 nonusers, 90.9% versus 57.1%, greater annualized FBTCS frequency, 3.00 versus 1.32, higher ASM burden, 3.05 versus 2.21 medications, and shorter time from epilepsy onset to EMU admission, 5.0 versus 18.1 years.
Dr. Caplan’s Clinical Verdict: The signal is clinically important but not causal. Frequent cannabis use should trigger a more detailed seizure, product, THC, CBD, adherence, sleep, and safety review, not an automatic assumption that cannabis is the cause.
Study Overview: Cannabis use has increased substantially, with modern products characterized by high tetrahydrocannabinol concentrations and variable composition. The relationship between frequent cannabis use and epilepsy outcomes remains uncertain. We examined the association between frequent cannabis use and epilepsy severity, clinical phenotype, and imaging characteristics in patients admitted to an epilepsy monitoring unit (EMU). This retrospective cohort study included adults with drug-resistant epilepsy admitted to a tertiary care EMU. Patients were classified based on cannabis use documented in the electronic medical record over the year prior to admission. Frequent use was defined as cannabis use on ≥20 days/month; patients with low use were excluded. Primary outcomes included markers of epilepsy severity, including time from epilepsy onset to EMU admission, presence and frequency of focal to bilateral tonic-clonic seizures (FBTCS), and antiseizure medication (ASM) burden. Secondary analyses evaluated epilepsy syndrome and mesial temporal lobe volumetric measures. Sixty-four patients were included (42 nonusers and 22 frequent users). Frequent cannabis use was associated with shorter time from epilepsy onset to EMU admission (mean [SD] = 5.0 [4.2] vs. 18.1 [16.3] years, p = .004), higher prevalence of FBTCS (90.9% vs. 57.1%, p = .04), greater annualized FBTCS frequency (mean [SD] = 3.00 [3.63] vs. 1.32 [3.87], p = .003), and higher ASM burden (mean [SD] = 3.05 [1.00] vs. 2.21 [1.14], p = .027). All frequent cannabis users had temporal lobe epilepsy (TLE), although the between-group difference in TLE prevalence was not statistically significant. No significant group differences were observed in imaging analysis. In this cohort of patients with drug-resistant epilepsy, frequent cannabis use was associated with markers of increased epilepsy severity, including higher FBTCS burden, shorter time to specialized EMU evaluation, and greater ASM requirements. Prospective studies using objective cannabis exposure measures are needed to clarify the relationship between cannabis use and epilepsy outcomes.
Primary Source & Scope: Published in Epilepsia (2026Sep28) conducted by Santiago Philibert-Rosas, Kaitlin A Guston, Mariel Kalkach-Aparicio, Abigail Keller et al.. Primary Source Link | Primary Record: DOI: 10.1002/epi.70456 | PMID: 42803888
Clinical research into Frequent cannabis use and the association with sei is progressing through rigorously documented peer-reviewed cohorts.
Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries.
The most important feature of this paper is the specific seizure signal, not the cannabis label alone. Focal to bilateral tonic-clonic seizures are among the outcomes clinicians most want to prevent, and the frequent-use group showed both higher prevalence and higher annualized frequency. That makes the association clinically relevant even though the study cannot decide whether cannabis was a driver, marker, or attempted self-treatment response to more severe disease.
The paper also exposes a recurring weakness in cannabis research: exposure is too often documented as use or nonuse when the pharmacology depends on dose, THC potency, CBD content, route, regularity, and product reliability. A patient using nightly high-THC concentrates is not pharmacologically equivalent to a patient using a consistent CBD-dominant preparation, yet both may be captured under broad cannabis categories in routine records.
How to Interpret This Clinical Study
Navigating biomedical publications regarding Frequent cannabis use and the association wit requires reviewing study methodology and patient eligibility.
Three Rules for Critical Reading
Critical Rule
Separate association from causation because the study is retrospective and cannot determine whether cannabis worsened epilepsy or more severe epilepsy led to more cannabis use.
Critical Rule
Interrogate the exposure definition because use on at least 20 days per month does not specify THC dose, CBD dose, formulation, route, potency, or consistency.
Critical Rule
Focus on clinically meaningful endpoints because focal to bilateral tonic-clonic seizures, antiseizure medication burden, and EMU referral timing matter more than a generic cannabis user label.
CED Perspective Lens: Eight Clinical Viewpoints
Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives
Clinical Evidence Synthesis
This retrospective cohort examined 64 adults with drug-resistant epilepsy admitted to a tertiary epilepsy monitoring unit. Patients were classified as nonusers or frequent cannabis users, with frequent use defined as at least 20 days per month in the prior year. Low-frequency users were excluded, sharpening contrast but reducing generalizability.
Frequent users had more markers of severity: FBTCS prevalence was 90.9% versus 57.1%, annualized FBTCS frequency was 3.00 versus 1.32, and antiseizure medication burden was 3.05 versus 2.21 medications. These are associations within a selected EMU population, not proof of causation.
Patient Communication
For patients, the most useful message is neither reassurance nor alarm. Frequent cannabis use in this cohort traveled with more severe epilepsy features, especially focal to bilateral tonic-clonic seizures. That deserves discussion because these seizures carry higher injury risk, driving restrictions, and sudden unexpected death in epilepsy considerations.
Clinicians should ask nonjudgmentally about frequency, product type, THC percentage, CBD content, route, timing, missed medications, sleep disruption, and withdrawal patterns. A patient who uses cannabis daily should not abruptly stop without a seizure safety plan and medical supervision.
Dosing & Formulations
The study did not measure dose, cannabinoid ratios, terpene profile, route, dispensary source, or objective blood levels. That matters because frequent cannabis use may include high-THC inhaled products, balanced THC:CBD products, CBD-dominant preparations, or variable unregulated products with different neurologic effects.
Evidence for prescription cannabidiol in specific epilepsy syndromes should not be conflated with frequent use of modern high-THC cannabis. For clinical care, the missing dosing data are central, because seizure outcomes may differ by THC exposure, CBD dose, consistency, and medication interactions.
Safety & Side Effect Profile
The safety concern is not simply cannabis use, but cannabis use in a population already experiencing drug-resistant epilepsy. Higher focal to bilateral tonic-clonic seizure burden is clinically meaningful because these seizures are linked with injuries, emergency care, driving restrictions, and increased sudden unexpected death in epilepsy risk.
Cannabis may also affect cognition, anxiety, sleep architecture, medication adherence, and intoxication risk. In some patients, withdrawal, heavy THC exposure, or irregular use could plausibly destabilize seizure thresholds, but this paper cannot isolate those pathways.
Regulatory & Policy Dynamics
This paper sits at the intersection of medical cannabis access and epilepsy safety. Public policy often treats cannabis as a single exposure, while clinical epilepsy care requires distinctions among prescription cannabidiol, regulated dispensary products, high-THC flower, concentrates, edibles, and untested products.
Regulators and clinicians should not use this study to broadly deny access, because it is small and retrospective. Instead, the findings support better labeling, product testing, cannabinoid documentation, and clinical registries that capture seizure outcomes alongside verified cannabis exposure.
Mechanisms & Physiology
Mechanistically, the findings are plausible but unresolved. Cannabinoid signaling can influence excitatory and inhibitory neurotransmission, sleep, anxiety, inflammation, and network excitability. CBD has antiseizure evidence in defined syndromes, while THC can produce variable effects depending on dose, tolerance, formulation, and individual vulnerability.
All frequent cannabis users in the cohort had temporal lobe epilepsy, although the between-group difference in temporal lobe epilepsy prevalence was not statistically significant. Imaging did not show significant mesial temporal lobe volume differences, so physiology remains speculative.
Research Limitations
The study’s major limitation is confounding by indication and severity. Patients with more severe epilepsy may be more likely to use cannabis frequently for seizures, sleep, anxiety, pain, or medication side effects. That could make cannabis appear associated with worse epilepsy even if it is a response to severity.
Exposure was based on documentation in the electronic medical record rather than toxicology, product labels, purchase records, or measured cannabinoid levels. The sample included only 22 frequent users, limiting adjustment, subgroup analysis, and causal inference.
Future Outlook
The next useful studies should be prospective and should measure cannabis exposure objectively. That means capturing THC dose, CBD dose, formulation, route, timing relative to seizures, batch testing, blood or urine cannabinoid measures, antiseizure medication levels, sleep, adherence, and withdrawal episodes.
Clinically, the strongest future endpoint would be change in seizure frequency after standardized cannabis modification, not just comparison between users and nonusers. Randomized trials may be difficult, but prospective registries and pragmatic designs could meaningfully improve guidance.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Does this study prove cannabis causes more seizures in epilepsy?
No. It found an association between frequent cannabis use and higher seizure burden in a small retrospective cohort. It cannot determine whether cannabis worsened seizures or whether people with more severe epilepsy were more likely to use cannabis.
What counted as frequent cannabis use in this study?
Frequent use was defined as cannabis use on at least 20 days per month during the year before epilepsy monitoring unit admission. Patients with lower-frequency use were excluded from the comparison.
How many patients were included?
The study included 64 adults with drug-resistant epilepsy: 42 nonusers and 22 frequent cannabis users. This is a small sample, especially for drawing strong causal conclusions.
What seizure outcome looked worse among frequent cannabis users?
Frequent users had a higher prevalence of focal to bilateral tonic-clonic seizures, 90.9% versus 57.1%, and higher annualized FBTCS frequency, 3.00 versus 1.32. These seizure types are clinically important because they carry greater safety risks.
Did frequent cannabis users take more seizure medications?
Yes. Frequent users had a higher antiseizure medication burden, averaging 3.05 medications compared with 2.21 in nonusers. This may reflect more severe epilepsy, more treatment resistance, or other clinical differences.
Was this about prescription CBD or general cannabis use?
The summary describes cannabis use documented in the medical record, not a controlled prescription CBD trial. The study did not define precise THC dose, CBD dose, formulation, or cannabinoid ratio, which limits interpretation.
Should a patient with epilepsy stop cannabis immediately after reading this?
No abrupt change is advisable without medical guidance. Sudden cessation, sleep disruption, anxiety rebound, or withdrawal could theoretically affect seizure control in some patients. A supervised plan is safer.
What should clinicians ask patients with epilepsy about cannabis?
Clinicians should ask about frequency, route, THC potency, CBD content, timing, product consistency, reasons for use, missed antiseizure medication doses, sleep, alcohol or other substances, and any seizure changes after starting, stopping, or changing products.
Did brain imaging explain the association?
No significant group differences were found in the imaging analysis of mesial temporal lobe volumetric measures. The study therefore does not show that frequent cannabis users had a distinct structural imaging pattern explaining seizure burden.
What is the safest clinical takeaway for patients?
Patients with drug-resistant epilepsy who use cannabis frequently should disclose it to their epilepsy clinician and review seizure logs, medication adherence, product details, and safety precautions. The goal is risk reduction, not blame.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
